Crinetics Pharmaceuticals, Inc.
CRNX
$84.70
$0.260.31%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 42.16M | 18.07M | 7.70M | 1.54M | 1.39M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 42.16M | 18.07M | 7.70M | 1.54M | 1.39M |
| Cost of Revenue | 376.88M | 357.18M | 333.13M | 313.57M | 285.01M |
| Gross Profit | -334.72M | -339.11M | -325.44M | -312.04M | -283.62M |
| SG&A Expenses | 214.37M | 206.64M | 191.33M | 165.81M | 139.44M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 591.25M | 563.81M | 524.47M | 479.38M | 424.45M |
| Operating Income | -549.09M | -545.74M | -516.77M | -477.85M | -423.06M |
| Income Before Tax | -501.43M | -496.21M | -465.14M | -423.10M | -369.83M |
| Income Tax Expenses | 180.00K | 180.00K | 180.00K | -- | -- |
| Earnings from Continuing Operations | -501.61 | -496.39 | -465.32 | -423.10 | -369.83 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -501.61M | -496.39M | -465.32M | -423.10M | -369.83M |
| EBIT | -549.09M | -545.74M | -516.77M | -477.85M | -423.06M |
| EBITDA | -544.85M | -541.62M | -512.88M | -474.16M | -419.62M |
| EPS Basic | -5.05 | -5.13 | -4.94 | -4.53 | -4.11 |
| Normalized Basic EPS | -3.15 | -3.21 | -3.09 | -2.83 | -2.57 |
| EPS Diluted | -5.05 | -5.13 | -4.94 | -4.53 | -4.11 |
| Normalized Diluted EPS | -3.15 | -3.21 | -3.09 | -2.83 | -2.57 |
| Average Basic Shares Outstanding | 398.97M | 387.20M | 376.20M | 372.60M | 358.48M |
| Average Diluted Shares Outstanding | 398.97M | 387.20M | 376.20M | 372.60M | 358.48M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |